---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-021379"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T08:28:47.172302+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics FY2024 cash $11.6M; VCN-01 Phase 2b data due Q2 2025

## Summary
- Cash and cash equivalents $11.6M as of Dec 31, 2024; expected runway into Q3 2025.
- R&D expenses decreased 16% to $12.0M; G&A expenses increased 4% to $7.4M.
- VIRAGE Phase 2b enrollment completed (92 evaluable patients); topline data expected Q2 2025.
- FDA Fast Track for VCN-01 in PDAC; FDA and EMA provided Phase 3 trial design guidance.
- Audited 10-K includes going concern explanatory paragraph from independent auditor.

## SEC filing metadata
- accession: 0001104659-25-021379
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/0001104659-25-021379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-021379
- JSON: https://secwatch.observer/filing/0001104659-25-021379.json
- Plain text: https://secwatch.observer/filing/0001104659-25-021379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.